Lamotrigine levels can rise when combined with hormonal contraceptives, potentially increasing the risk of side effects. Your prescriber may adjust the lamotrigine dose or recommend a different contraceptive method.
Stop the medication immediately and seek medical attention. Even a mild rash can herald a serious reaction such as Stevens-Johnson syndrome, especially during the first eight weeks of therapy.
Yes, but keep the medication in its original labelled container, carry a copy of the prescription, and be aware of any country-specific import restrictions on controlled medicines.
Lamotrigine primarily targets depressive episodes and has a lower risk of weight gain and thyroid dysfunction compared with lithium, which is more effective for classic manic episodes. Choice of therapy depends on individual symptom patterns and tolerability.
Both contain the same active ingredient and are bioequivalent. However, inactive ingredients differ, which may affect tolerability for some patients. Discuss any switch with your pharmacist or prescriber.
Excessive alcohol can lower the seizure threshold and increase dizziness, potentially compromising safety. Moderate intake is generally permissible, but you should discuss your drinking habits with your doctor.
Routine lamotrigine blood level monitoring is not required for most patients, but liver and kidney function tests may be performed periodically, especially if you have underlying organ disease.
The variety of tablet strengths facilitates precise titration during the initial weeks of therapy, helping to minimise the risk of skin reactions while achieving the therapeutic dose.
Lamotrigine is generally weight-neutral; most patients do not experience significant changes in body weight while on the medication.
Lamotrigine is listed on the NHS Drug Tariff and is typically prescribed at no charge to eligible patients. For specific cost information, contact your local pharmacy or the NHS prescription service.
Lamictal is the brand name for the medication lamotrigine, a prescription-only drug approved in the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA). It is supplied as a pill and is available in four strengths: 25 mg, 50 mg, 100 mg, and 200 mg. Lamotrigine belongs to the neurology therapeutic class and is primarily used to treat certain seizure disorders and to stabilise mood in bipolar disorder. The product is manufactured by GlaxoSmithKline (GSK) and is distributed under a prescription label in the UK.
Lamotrigine stabilises neuronal activity by inhibiting voltage-gated sodium channels. This action reduces the release of excitatory neurotransmitters, particularly glutamate and aspartate, which helps to prevent the rapid, uncontrolled firing of brain cells that underlies seizures and mood swings. The drug is absorbed well after oral administration, reaching peak plasma concentrations within 1-4 hours. It is partially metabolised by the liver enzyme UGT1A4 and eliminated primarily via the kidneys. The relatively long half-life (approximately 25 hours in adults) allows for once-daily dosing once the titration phase is complete.
Lamotrigine is approved by the MHRA for the following indications:
These approvals are based on clinical trials that demonstrated reductions in seizure frequency and a lower risk of depressive relapse in bipolar patients when lamotrigine is used as part of a comprehensive treatment plan.
Lamotrigine has been investigated for several off-label indications. Where evidence exists, it is highlighted below, together with the required disclaimer.
Off-label use of lamotrigine requires medical supervision and an individualized risk-benefit assessment. These applications are not approved by the MHRA and should only be considered when a qualified healthcare professional deems them appropriate.
These effects are generally transient and may improve as the body adjusts to the medication.
Patients should provide a complete medication list, including over-the-counter products and herbal supplements, to their prescriber before initiating lamotrigine.
Lamotrigine dosing follows a titration schedule to minimise rash risk. The exact regimen should be confirmed by a prescriber.
Epilepsy (adult)
Week 1-2: 25 mg once daily (one 25 mg tablet)
Week 3-4: 50 mg once daily (one 50 mg tablet)
Week 5-6: 100 mg once daily (one 100 mg tablet)
Maintenance: 200 mg daily (one 200 mg tablet) - may increase to 400 mg total per day if seizure control is insufficient, using two 200 mg tablets.
Bipolar disorder (adult)
Week 1: 25 mg once daily
Week 2: 50 mg once daily
Week 3: 100 mg once daily
Week 4: 200 mg once daily (maintenance).
If valproic acid is co-prescribed, the titration pace is halved and the maximum daily dose should not exceed 200 mg.
Abrupt cessation can increase seizure frequency. A gradual taper is recommended, typically reducing the dose by 25 % every 1-2 weeks under medical supervision. For bipolar disorder, stopping lamotrigine abruptly may precipitate mood destabilisation.
This article provides educational information about Lamictal and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
